B of A Securities Downgrades Organon to Underperform, Lowers Price Target to $25
B of A Securities analyst Jason Gerberry downgrades Organon (NYSE:OGN) from Neutral to Underperform and lowers the price target from $37 to $25.
How Is The Market Feeling About Organon?
Organon's (NYSE:OGN) short percent of float has risen 11.91% since its last report. The company recently reported that it has 5.94 million shares sold short, which is 2.63% of all regular shares that are available for trading.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 361 companies set new 52-week lows.
EXCLUSIVE: Roofstock onChain Launches Real Estate NFT Marketplace Powered By Origin Protocol
Origin Protocol, a Web3 pioneer in NFTs and DeFi, has partnered with the online real estate investment platform Roofstock to bring blockchain innovation to the real estate industry.
This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%
Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading.
Piper Sandler Upgrades Organon to Overweight, Lowers Price Target to $34
Piper Sandler analyst David Amsellem upgrades Organon (NYSE:OGN) from Neutral to Overweight and lowers the price target from $37 to $34.
This Women Health Stock Gets Analyst Downgrade On ‘Approvability Issues, Restructuring’
HC Wainwright has downgraded ObsEva SA (NASDAQ:OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified…